Effects of angiotensin II and insulin on ERK1/2 activation in fibroblasts from hypertensive patients

American Journal of Hypertension

Volumn 17, Issue 7, 2004, Pages 604-610

  Sartori, Michelangelo ^a   Ceolotto, Giulio ^a   Papparella, Italia ^a   Baritono, Elisabetta ^a   Ciccariello, Laura ^a   Calò, Lorenzo ^a   Leoni, Matteo ^a   Semplicini, Andrea ^a,b  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

^b UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

angiotensin II; Diabetes; Hypertension; Insulin; Insulin resistance; Mitogen activated protein kinase; Signal transduction

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ENZYME ANTIBODY; INSULIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1;

ADULT; ANTIBODY SPECIFICITY; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR RESPONSE; CELL PROLIFERATION; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; EXTRACELLULAR MATRIX; FEMALE; FIBROBLAST CULTURE; HUMAN; HUMAN CELL; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SKIN FIBROBLAST; WESTERN BLOTTING;

ADULT; ANGIOTENSIN II; BIOLOGICAL MARKERS; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; FEMALE; FIBROBLASTS; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; ITALY; MALE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PHOSPHOTRANSFERASES; RECEPTOR, ANGIOTENSIN, TYPE 1; TIME FACTORS; TREATMENT OUTCOME; VASOCONSTRICTOR AGENTS;

EID: 3042647159     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjhyper.2004.02.017     Document Type: Article

References (29)

1. Devereux R.B., Roman M.J., Ganau A., de Simone G., Okin P.M., Kligfield P. Cardiac and arterial hypertrophy and atherosclerosis in hypertension. Hypertension. 23:1994;802-809
2. Lip G.Y., Felmeden D.C., Li-Saw-Hee F.L., Beevers D.G. Hypertensive heart disease. A complex syndrome or a hypertensive 'cardiomyopathy'? Eur Heart J. 21:2000;1653-1665
3. Gibbons G.H., Dzau V.J. The emerging concept of vascular remodeling. N Engl J Med. 330:1994;1431-1438
4. Griffin S.A., Brown W.C., MacPherson F., McGrath J.C., Wilson V.G., Korsgaard N., Mulvany M.J., Lever A.F. Angiotensin II causes vascular hypertrophy in part by a non-pressor mechanism. Hypertension. 17:1991;626-635
5. Dinh D.T., Frauman A.G., Johnston C.I., Fabiani M.E. Angiotensin receptors distribution, signalling and function. Clin Sci (Lond). 100:2001;481-492
6. Tharaux P.L., Chatziantoniou C., Fakhouri F., Dussaule J.C. Angiotensin II activates collagen I gene through a mechanism involving the MAP/ER kinase pathway. Hypertension. 36:2000;330-336
7. Wetzker R., Bohmer F.D. Transactivation joins multiple tracks to the ERK/MAPK cascade. Nat Rev Mol Cell Biol. 4:2003;651-657
8. Pearson G., Robinson F., Beers Gibson T., Xu B.E., Karandikar M., Berman K., Cobb M.H. Mitogen-activated protein (MAP) kinase pathways regulation and physiological functions. Endocr Rev. 22:2001;153-183
9. Pessin J.E., Saltiel A.R. Signaling pathways in insulin action molecular targets of insulin resistance. J Clin Invest. 106:2000;165-169
10. Cusi K., Maezono K., Osman A., Pendergrass M., Patti M.E., Pratipanawatr T., DeFronzo R.A., Kahn C.R., Mandarino L.J. Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. J Clin Invest. 105:2000;311-320
11. Montagnani M., Golovchenko I., Kim I., Koh G.Y., Goalstone M.L., Mundhekar A.N., Johansen M., Kucik D.F., Quon M.J., Draznin B. Inhibition of phosphatidylinositol 3-kinase enhances mitogenic actions of insulin in endothelial cells. J Biol Chem. 277:2002;1794-1799
12. Reaven G.M. Insulin resistance/compensatory hyperinsulinemia, essential hypertension, and cardiovascular disease. J Clin Endocrinol Metab. 88:2003;2399-2403
13. Ceolotto G., Valente R., Baritono E., Reato S., Iori E., Monari A., Trevisan R., Semplicini A. Effect of insulin and angiotensin II on cell calcium in human skin fibroblasts. Hypertension. 37:2001;1486-1491
14. Guidelines Subcommittee: 2003 European Society of Hypertension- European Society of Cardiology Guidelines for the Management of Arterial Hypertension. J Hypertension 2003;21:1011-1053.
15. Mari A., Pacini G., Murphy E., Ludvik B., Nolan J.J. A model-based method for assessing insulin sensitivity from the oral glucose tolerance test. Diabetes Care. 24:2001;539-548
16. Servant M.J., Giasson E., Meloche S. Inhibition of growth factor-induced protein synthesis by a selective MEK inhibitor in aortic smooth muscle cells. J Biol Chem. 271:1996;16047-16052
17. Wilkie N., Ng L.L., Boarder M.R. Angiotensin II responses of vascular smooth muscle cells from hypertensive rats enhancement at the level of p42 and p44 mitogen activated protein kinase. Br J Pharmacol. 122:1997;209-216
18. Kubo T., Ibusuki T., Saito E., Kambe T., Hagiwara Y. Different activation of vascular mitogen-activated protein kinases in spontaneously and DOCA-salt hypertensive rats. Eur J Pharmacol. 400:2000;231-237
19. Laplante M.A., Wu R., El Midaoui A., de Champlain J. NAD(P)H oxidase activation by angiotensin II is dependent on p42/44 ERK-MAPK pathway activation in rat's vascular smooth muscle cells. J Hypertens. 21:2003;927-936
20. + exchanger isoform-1 of human lymphoblasts in hypertension. Metabolism. 46:1997;297-302
21. Touyz R.M., He G., Wu X.H., Park J.B., Mabrouk M.E., Schiffrin E.L. Src is an important mediator of extracellular signal-regulated kinase 1/2-dependent growth signaling by angiotensin II in smooth muscle cells from resistance arteries of hypertensive patients. Hypertension. 38:2001;56-64
22. Kagiyama S., Eguchi S., Frank G.D., Inagami T., Zhang Y.C., Phillips M.I. Angiotensin II-induced cardiac hypertrophy and hypertension are attenuated by epidermal growth factor receptor antisense. Circulation. 106:2002;909-912
23. Nebreda A.R. Inactivation of MAP kinases. Trends Biochem Sci. 19:1994;1-2
24. Duff J.L., Monia B.P., Berk B.C. Mitogen-activated protein (MAP) kinase is regulated by the MAP kinase phosphatase (MKP-1) in vascular smooth muscle cells. Effect of actinomycin D and antisense oligonucleotides. J Biol Chem. 270:1995;7161-7166
25. Begum N., Song Y., Rienzie J., Ragolia L. Vascular smooth muscle cell growth and insulin regulation of mitogen-activated protein kinase in hypertension. Am J Physiol. 275:1998;C42-C49
26. Begum N., Ragolia L. High glucose and insulin inhibit VSMC MKP-1 expression by blocking iNOS via p38 MAPK activation. Am J Physiol Cell Physiol. 278:2000;C81-C91
27. Reaven G. Insulin resistance, hypertension, and coronary heart disease. J Clin Hypertens. 5:2003;269-274
28. Ogihara T., Asano T., Ando K., Chiba Y., Sakoda H., Anai M., Shojima N., Ono H., Onishi Y., Fujishiro M., Katagiri H., Fukushima Y., Kikuchi M., Noguchi N., Aburatani H., Komuro I., Fujita T. Angiotensin II-induced insulin resistance is associated with enhanced insulin signaling. Hypertension. 40:2002;872-879
29. Fukuda N., Satoh C., Hu W.Y., Nakayama M., Kishioka H., Kanmatsuse K. Endogenous angiotensin II suppresses insulin signaling in vascular smooth muscle cells from spontaneously hypertensive rats. J Hypertens. 19:2001;1651-1658